申请人:Sorrento Therapeutics, Inc.
公开号:US20170137539A1
公开(公告)日:2017-05-18
Provided are bispecific antibody compounds having the Formula I:
wherein, FAB
1
, FAB
2
, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
提供的双特异性抗体化合物具有以下式I:其中,FAB1、FAB2和—X—如本文所定义。提供的双特异性抗体化合物可用作靶分子的调节剂,包括CD3、PSMA、CD19、CXCR5、CD33、PDL1、VEGFR2、cMet或Axl,并且在治疗一个或多个疾病方面是有用的。